Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.

BMC cancer - 11 Nov 2024

Cai Xiaojun, Lin Jing, Li Caili, Xu Ting, Chen Chuanben, Lan Bin, Wang Xuefeng, Bai Shengjie, Huang Yufang, Zhang Huishan, Si Lu, Chen Yu

Abstract excerpt

BACKGROUND: Mesenchymal epithelial transition factor (MET) variant is an independent prognostic factor for worse prognosis in patients with lung cancer or gastroesophageal adenocarcinoma. MET gene variants can be regarded as a subtype of melanoma but there is a lack of studies regarding the frequency of MET genetic alterations and the efficacy of immunotherapy in melanoma patients. The purpose of this study is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Melanoma

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins c-met

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39528978
DOI: 10.1186/s12885-024-13163-z
PMCID: PMC11555915

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.PMID 39528978Read ↗

Characterizing the Mutational Landscape of In-Transit Melanoma Metastases.Semantic proximity Read ↗

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.Semantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

A novel patient-derived cutaneous melanoma cell line reveals key features of metastatic melanomaSemantic proximity Read ↗

Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.Semantic proximity Read ↗

Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications.Semantic proximity Read ↗

Functional and sensitivity profiling of the <i>KIT</i> Mutation Landscape in MelanomaSemantic proximity Read ↗

[BRAF mutation: a novel approach in targeted melanoma therapy].Semantic proximity Read ↗

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.